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Abstract
Objective: Factors influencing the outcome of anti-VEGF treatment in neovascular AMD are still investigated. We analyzed
the impact of a loading phase, the significance of an initial response for the long-term and the effect of the CFH
polymorphism (p.His402Tyr) on treatment outcome.
Methods: Patients treated with ranibizumab for neovascular AMD were analyzed over a period of 24 months by assessing
effects of loading phase, initial response and genotype of CFH rs1061170 (c.1204C.T, p.His402Tyr).
Results: 204 eyes were included. A change of +5.0 [21;+11] letters and +1.5 [25.5;+9.5] was observed with a median of 4
[3;7] and 10 [7;14] ranibizumab injections during 12 and 24 months, respectively. Loading phase was no significant
predictor for treatment as VA outcome in eyes with and without loading phase was similar (p = 0.846 and p= 0.729) at 12
and 24 months. In contrast, initial response was a significant predictor for improving vision of 5 or more letters at 12
(p = 0.001; OR= 6.75) and 24 months (p = 0.01; OR= 4.66). Furthermore, the CT genotype at CFH rs1061170 was identified as
a significant predictor for a favorable VA outcome at 12 and 24 months (OR= 6.75, p = 0.001 and OR= 4.66, p = 0.01).
Conclusions: Our data suggest that clinical decisions regarding treatment may be guided by observing patients’ initial
response as well as their genotype of SNP rs1061170, while the criterion of loading phase may not bear the customary
value.
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Introduction
Age-related macular degeneration (AMD) is the leading cause of
severe visual impairment in the elderly population in developed
countries [1]. For example, in Australia where AMD is the leading
cause of blindness [2]. AMD affects 1 in 7 Australians over the age
of 50 years with increasing incidence with age [3]. Overall, 17700
new patients per year are diagnosed having AMD [4]. Advanced
stages present either as geographic atrophy or choroidal
neovascularization [5]. Anti-vascular-endothelial growth-factor
(VEGF) antibodies have revolutionized the treatment of neovas-
cular AMD. The most widely used compounds are ranibizumab
(LucentisH, Novartis, Basel, Switzerland; Genentech Inc., South
San Francisco, CA, USA) and bevacizumab (AvastinH, Roche,
Basel, Switzerland; Genentech Inc., South San Francisco, CA,
USA). In January 2007, ranibizumab was approved by the FDA
for neovascular AMD after having shown to improve visual acuity
with monthly injections in patients with neovascular AMD in the
MARINA [6] and ANCHOR [7] studies and has now become the
standard treatment for neovascular AMD.
The study regimen of monthly injections, as applied in
MARINA and ANCHOR, can hardly be realized in a typical
clinical setting as a monthly schedule results in a heavy burden of
treatment for both the patient and family members that often
accompany elderly and visually impaired patients to the clinic
visits. Given the high number of patients affected, manageability of
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high patient numbers requiring potentially a lifelong treatment has
become a significant issue. Therefore further studies have been
conducted to identify treatment schedules that achieve successful
treatment results with a lower number of injections [8–12]. Widely
applied is a so-called loading phase with three initial consecutive
intravitreal injections of ranibizumab followed by a PRN scheme
(pro re nata) [9,10,13]. To date, there is no convincing evidence
though to support the idea that a loading phase is superior to an
immediate PRN scheme, where the re-treatment regimen is
guided by both morphological and clinical parameters [14,15].
Since there is a substantial number of patients presenting an
unfavorable long-term outcome, i.e., loss of vision despite
continued treatment [16], factors other than treatment regimen
possibly influencing treatment responses are scrutinized and
indicators for response to treatment are evaluated.
The initial response to anti-VEGF therapy was suggested to be
indicative for the long-term response, but available data so far are
contradicting [16–18].
On the other hand, while the influence of genetic risk factors on
AMD development is well established [19–23], there is now
evidence showing that genetic variants also influence treatment
results and seem responsible for the variation in outcome despite
similar treatment patterns [24–29]. Specifically, we have pre-
viously shown that the CC genotype at CFH rs1061170 is
associated with an unfavorable visual acuity course after
12 months of ranibizumab therapy [24]. Despite the progress
made, a better understanding of the impact of different factors on
the treatment outcome is still somewhat unclear, partially due to
the fact that hypotheses are tested in different study populations
and, as a consequence, results are not always comparable.
Additionally, many studies had rather short-term endpoints, i.e.
6 months or 12 months of follow-up only. The work presented
here offers the advantage of analyzing a single study population
over an extended period of 24 months. It addresses the following
questions: (i) Does a loading phase have an influence on the long-
term treatment outcome? (ii) Is an initial response predictive of
a favorable long-term outcome, i.e., sustained gain of vision? and
(iii) Are genetic predictors accountable not only after 12 months of
treatment but also for a long-term treatment of 24 months?
Methods
This is a retrospective analysis of patients treated for
neovascular AMD with ranibizumab at the Department of
Ophthalmology at the University Hospital Zurich, Switzerland.
The treatment regimen was physician-guided, patients were not
assigned to a predefined schedule. Patients with prior treatments
or treatments other than intravitreal ranibizumab were excluded.
A detailed description of the clinical data collection as well as
DNA preparation and genetic analysis for this study was published
previously [24]. Briefly, visual acuity was recorded using logMAR
charts. Patients were treated with 0.5 mg ranibizumab, adminis-
tered intravitreally. Subsequent injections were only performed if
signs of lesion activity (i.e. subretinal fluid, cystoid macular edema,
sub- or intraretinal bleeding, active lesion in fluorescein angiog-
raphy) were present. Follow up visits were scheduled monthly, but
could vary due to patients’ personal needs. The study was
conducted according to the Tenets of the Declaration of Helsinki
and approved by the local ethics committee.
Two response groups at 12 and 24 months after start of
treatment were established: good responders (GR) containing eyes
that had a 5 or more letter improvement compared to baseline and
poor responders (PR) comprising of eyes losing 5 or more letters
compared to baseline.
An initial loading phase was defined as the administration of
three consecutive intravitreal injections of ranibizumab in
4 weekly intervals at the start of the therapy, i.e. at baseline,
1 month and 2 months after baseline. To assess the effect of the
loading phase, eyes were allocated to two groups: those that had
received a loading phase and those that did not. The course of VA
at 12 and 24 months was compared between the two groups, i.e.,
loading phase vs. no loading phase, as well as clinical character-
istics (baseline VA, age, gender, injection frequency and visits) and
the distribution of the genotype of CFH rs1061170. The
distribution of eyes with and without loading phase to GR and
PR was analyzed.
An initial response to treatment was defined as an improvement
in visual acuity (VA) of 5 or more letters compared to the baseline
VA at 1, 2 and 3 months after commencing treatment.
Similar to the first analysis, the course of VA at 12 and
24 months was compared between the two groups, i.e. initial
response vs. no initial response, as well as the distribution of eyes
with and without initial response to GR and PR.
Genetic analysis was performed for the SNP CFH rs1061170 as
described [24]. Based on the genotype of CFH rs1061170, the
course of VA at 12 and 24 months was compared between groups
with respect to clinical characteristics (baseline VA, age, gender,
loading phase, injection frequency and visits) at 12 and 24 months
in GR and PR and the distribution of the CFH genotype at
rs1061170 were assessed.
Statistical Analysis
Statistical calculations were done using either commercially
available software packages (IBM SPSS Statistics 19, SPSS Inc.
Chicago, Il or SAS software, SAS Institute Inc., NC, USA) or open
access internet portals from http://in-silico.net/statistics. Nor-
mally distributed data are presented as mean6standard deviation
(SD), not-normal data are presented as median and interquartile
range [IQR]. Normality was assessed using the Shapiro-Wilks test.
Odds ratios from independent samples were compared as
described [24]. Odds ratios from 262 and 263 tables were
analyzed using Fisher’s exact test.
Table 1. Effects of genotype SNP rs1061170 at CFH.
Genotype
CC CT TT
N N N
change $
5 month 12
loss $5 letters 17 16 11
gain $5 letters 15 46 22
change $
5 month 24
loss $5 letters 17 14 12
gain $5 letters 10 28 17
Percentiles
month 12
25 20 19 16
75 7 30 14
Percentiles
months 24
25 14 12 12
75 5 22 14
Frequencies of genotypes are given for the groups with gain or loss of $5
letters as well as the upper and lower percentiles at 12 and 24 months after
treatment begin.
doi:10.1371/journal.pone.0042014.t001
Factors Influencing Outcome of Neovascular AMD
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Generalized estimation equation (GEE) methods were used
(binary outcome) in three separate models to analyze the
predictive value of loading phase, initial response and CFH
rs1061170 and to address the fact that in some patients both eyes
were included. Additional predictors were gender, age at baseline,
VA at baseline and lesion type.
The dependent variable (GR and PR at 12 and 24 months) was
coded binary, PR being the reference category. For binary
predictors the reference categories were: no loading phase, no
initial response, CC genotype and male gender. For the
categorical predictor lesion type, minimally classic was chosen as
reference category. VA at baseline and age at baseline were
entered as continuous variables. Since no difference in number of
injections, number of visits or injections/months could be
identified for any of the groups analyzed, number of injections
and visits were not included in the GEE modeling.
Results
Characteristics of the Study Population
Clinical and genotyping data were collected for 204 eyes. In 10
patients, both eyes were included in the analysis. 63.2% of the
patients were female. The average age in all patients at baseline
was 79.367.1 years. The mean baseline visual acuity in all eyes
(VA) was 55.2614.6 letters. 70.5% of all eyes showed an occult
lesion type at baseline, 12.3% had minimally classic and 17.2%
had predominantly classic lesions. The median number of
ranibizumab injections in all eyes after 12 and 24 months was 4
[3;7] and 10 [7;14], respectively. The median number of follow up
visits in all eyes was 9 [9;11] after 12 months and 20.5 [18;23] over
the period of 24 months. In all eyes, a change in VA of +5.0
[21;+11] letters was achieved at 12 months and +1.5 [25.5;+9.5]
letter 24 months from baseline. No statistically significant differ-
ences were found between the three different lesion types (occult,
minimally classic, predominantly classic) with respect to age
(Fig. 1A), baseline VA (Fig. 1B), VA course (Fig. 1C), number of
visits and injections (Fig. 1D and E), CFH genotype, eyes with
loading phase, and eyes with initial response (Fig. 1F). Analysis of
the distribution of the SNP rs1061170 at CFH showed that 46.1%
(N=94) of all patients carried the CT genotype, while 27%
(N=55) had the CC and 27% (N=55) the TT genotype. Of the
204 eyes, 83 eyes (40.6%) showed a change of 5 or more letters
after 12 months. 77 eyes (37.7%) experienced a loss of 5 or more
letters after 12 months. After 24 months 55 eyes (37.6%) of 146
eyes gained 5 or more letters, while 48 eyes (32.8%) lost 5 or more
letters. In 58 eyes no VA data was available at 24 months after
baseline.
Loading Phase
Of the 204 eyes in the study, 58 (28.4%) initially received three
consecutive intravitreal injections of ranibizumab (loading phase).
No statistically significant differences were found with respect to
age (Fig. 2A), baseline VA (Fig. 2B), number of visits and number
of injections between eyes with and without loading phase (Fig. 2D
and E). The distribution of the CFH polymorphism between the
two groups was comparable (P = 0.72, Fig. 2F). VA at 12 and
24 months after baseline did not show significant differences
(p = 0.846 and p= 0.729, Fig. 2C). GEE analysis did not identify
loading phase to be significant predictor with respect to GR/PR at
12 and 24 months (p = 0.881 and p= 0.472, respectively).
Initial Response
An initial improvement of 5 or more letters at 1, 2 and
3 months after commencement of treatment (initial response) was
achieved in 47 eyes (23%). 16 (34%) of these also belonged to the
group of eyes that had received a loading phase. No statistically
significant difference was found in the proportions of eyes showing
an initial gain between eyes that had received a loading phase and
those that did not (p = 0.3591). No statistically significant
differences were found for age (Fig. 3A), baseline VA (Fig. 3B),
VA course (Fig. 3C), number of visits and number of injections
(Fig. 3D and E). Of the 47 eyes with an initial response to
treatment, 74.5% maintained the improvement of 5 or more
letters at 12 months and 66.6% maintained the initial response
until 24 months. GEE analysis revealed that an initial response is
a significant predictor for improving vision of 5 or more letters at
12 (p = 0.001; OR=6.75, CI 2.17–20.98) and 24 months after
baseline (p = 0.01; OR=4.66, CI 1.44–15.03). Importantly, of the
157 eyes that did not show an initial response, 30.6% showed an
increase of 5 or more letters 12 months from baseline and 29.2%
at 24 months from baseline. The distribution of the genotypes for
CFH polymorphism rs1061170 was not significantly different
between eyes that showed an initial gain and those that did not
(p = 0.5133, Fig. 3F).
CFH Genotype
The distribution of the possible genotypes at CFH rs1061170
between the two groups GR and PR ($5 letters vs. #5 letters
change compared to baseline) showed statistically significant
differences both at 12 and 24 months after baseline (Table 1).
The CC genotype at CFH rs1061170 (homozygous for His at
protein position 402 in CFH) was found at a statistically significant
higher frequency in the PR group at 12 and 24 months
(p = 0.0174 and p= 0.0236). GEE analysis revealed that the CT
genotype is a significant predictor for a favorable VA outcome
both at 12 and 24 months (OR=6.75, p = 0.001 and OR=4.66,
p = 0.01, respectively). No statistically significant differences
between the three genotype groups were found for gender, age
at baseline, lesion type, loading phase, initial response and baseline
VA. For comparison with our previously published data [24] we
also assessed treatment response by defining good and poor
responders according to the grouping of percentiles (75th
percentile and 25th percentile; Table 1). With this higher
discriminatory power the differences in the genotype distribution
were even more pronounced. The statistical significance level for
the CC genotype and poor response was P= 0.0082 at 12 months
and P=0.0167 at 24 months (Table 2).
Interaction effects of loading phase and CFH genotype as well as
the initial response and CFH genotype could not be identified.
Discussion
We were able to identify two robust significant predictors for
a favorable long-term outcome in neovascular AMD treatment
with ranibizumab. The CFH genotype as well as the initial
response both shows statistically significantly association with
a good long-term VA course. The effects of the CFH genotype and
the initial response seem to be independent, i.e. a patient carrying
the CT genotype at CFH rs1061170 and showing an initial
response does not double the likelihood of experiencing a good VA
course over the long term in comparison with a patient who
‘‘only’’ carries either variable. The loading phase, on the other
hand, does not seem to positively influence the VA in the long
term.
In nowadays-busy clinical settings, monthly injections of
ranibizumab are hardly feasible due to increasing numbers of
patients amenable for treatment and the high workload associated
to it. Consequently, different therapeutic regimens were elaborat-
Factors Influencing Outcome of Neovascular AMD
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Figure 1. Overview of three different lesion-types. Values are displayed for age at baseline (A), visual acuity at baseline (B), VA at 12 and
24 months (C), number of visits in 12 and 24 months (D), total injections in 12 and 24 months (E) and the distribution of genotypes (F). Symbols show
the median while whiskers indicate the interquartile range. No statistically significant differences are found.
doi:10.1371/journal.pone.0042014.g001
Figure 2. Overview of the loading phase groups. Values are displayed for age at baseline (A), visual acuity at baseline (B), VA at 12 and
24 months (C), number of visits in 12 and 24 months (D), total injections in 12 and 24 months (E) and distribution of CFH genotypes (F) in the loading
phase groups. Symbols show the median while whiskers indicate the interquartile range. No statistically significant differences are found.
doi:10.1371/journal.pone.0042014.g002
Factors Influencing Outcome of Neovascular AMD
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ed and have been tested. The most consistent strategy applied by
clinicians is the initial loading phase consisting of three consecutive
intravitreal injections. This regimen was first introduced by the
PrONTO study [9]. The evidence available from many phase III
clinical trials (e.g. PIER [10], SAILOR [30], SUSTAIN [17] and
EXCITE [18]) has been assessed by an international retina expert
panel suggesting a superiority of an initial loading phase followed
by a monthly monitoring [11]. However, these studies always
evaluated a flexible strategy after the initiation phase. To our
knowledge there has not been a study assessing the efficacy of the
loading phase with respect to the long-term response. Our analysis
did not reveal a beneficial outcome for patients who received
a loading phase compared to those who did not receive one. This
finding is important because it indicates that perhaps many AMD
patients do not necessarily need three consecutive initial anti-
VEGF injections in order to achieve a long-term success. The
OCT and clinical findings guided administration of anti-VEGF
from the beginning seems to be sufficient in distinguishing between
patients who continue to show signs of lesion activity after the first
injection and hence need repeated injections and those patients
who are ‘‘dry’’ after less than three injections.
The initial response, on the other hand, is of high prognostic
value. In the MARINA study patients with an initial response
(defined as VA change .0) gained 13 letters logMAR after
12 months compared to the loss of 3 letters logMAR of initial non-
responders (VA change ,0) [6]. The PIER trial showed that
a smaller proportion of initial gainers (40%) maintain their initial
gain after 12 months, but all the remaining initial gainer still fare
better than patients with no initial gain (defined as VA change.0)
[10]. In our study, we defined the initial gain as increase of 5 or
more letters logMAR at 1, 2 and 3 months from baseline. With
this definition only 23% of the eyes fulfilled the criteria, but
approximately 75% of these eyes maintained the increase of 5 or
more letters logMAR over a period of 12 months and 67%
Figure 3. Overview of the initial response groups. Values are displayed for age at baseline (A), visual acuity at baseline (B), VA at 12 and
24 months (C), number of visits in 12 and 24 months (D), total injections in 12 and 24 months (E) and distribution of CFH genotypes (F) in the initial
response groups. Symbols show the median while whiskers indicate the interquartile range. No statistically significant differences are found.
doi:10.1371/journal.pone.0042014.g003
Table 2. Effects of genotype SNP rs1061170 at CFH.
genotype OR LL UL Fisher’s Exact
change
$5 month
12
CC vs. CT 3.26 1.33 7.99 0.0121 0.0326
CC vs. TT 2.27 0.83 6.18 0.1361
CC vs. CT/TT 2.85 1.25 6.52 0.0174
change
$5 month
24
CC vs. CT 3.40 1.24 9.35 0.0251 0.0486
CC vs. TT 2.41 0.82 7.06 0.1194
CC vs. CT/TT 2.94 1.17 7.37 0.0236
percentiles
month 12
CC vs. CT 4.51 1.60 12.70 0.0041 0.0123
CC vs. TT 2.50 0.82 7.67 0.1687
CC vs. CT/TT 3.59 1.36 9.46 0.0082
percentiles
months 24
CC vs. CT 5.13 1.49 17.74 0.0103 0.0271
CC vs. TT 3.27 0.91 11.75 0.0772
CC vs. CT/TT 4.20 1.34 13.19 0.0167
Statistical assessment of the frequencies of the genotypes for the groups with
gain or loss of $5 letters as well as the upper and lower percentiles at 12 and
24 months after treatment begin. OR: odds ratio; LL and UL: lower and upper
limit.
doi:10.1371/journal.pone.0042014.t002
Factors Influencing Outcome of Neovascular AMD
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maintained the initial response until 24 months. More important-
ly, of the remaining eyes that did not experience an initial gain,
31% showed an increase of 5 or more letters after 12 and 29%
after 24 months from baseline. In other words: Of all eyes that
gained 5 or more letters after 12 and 24 months, 58% and 60%
had not shown an initial gain and yet did benefit from continued
therapy.
These findings are of high value for every ophthalmologist
confronted with questions of discussing a patient’s long-term VA
course, because the patient with an initial gain can be reassured
that his/her odds for a good course are positive and on the other
hand the patient with no initial gain can be encouraged that
a realistic probability does exist that she/he might be a long-term
gainer because the lack of an initial response does not exclude
a chance for improvement. Hence it is clinically important to
evaluate the initial response in each patient undergoing treatment
for wet AMD.
The third question we addressed concerned the genetic
influence on the long-term response to treatment. As previously
published, the CFH polymorphism rs1061170 (CC genotype,
homozygous for the His allele of CFH at position 402) seems to be
associated with a poor response to ranibizumab after 12 months
[24]. In the current analysis, we wanted to test whether these
findings are also true for the response after 24 months. The CT
genotype (heterozygous for the His and Tyr alleles at position 402
of CFH) was associated with an odds ratio of 3.2 and of 3.6 for
a VA increase of 5 or more letters after 12 and 24 months,
respectively. These results strengthen the impact of genetic
variations on the response to treatment. Possibly, variations in
the CFH gene influence the response to treatment through
modifying VEGF levels and expression of additional angiogenic
and inflammatory factors [31–33]. Alternatively, genetic variations
might also account for a different AMD ‘‘phenotype’’ with
a different composition of the lesion less susceptible to the
approved therapies [34]. These hypotheses though warrant further
research in the pathophysiology of AMD and the impact by the
genetic background.
The fact that in the study population the effect of CFH and
initial response on the final outcome seem to occur independently
may be due to several reasons. Patients with an initial increase may
have e.g. less aggressive lesions or a rather minor amount of
morphological damage whereas vision impairment could be
mainly caused by retinal edema and to a lesser extent by
neuroretinal damage, thus explaining the quick initial improve-
ment. However, further investigations of retinal pathology are
necessary to address these questions. As mentioned, the CFH
genotype may act via inflammatory or angiogenic pathways. This
may lead to a beneficial long-term effect contributing to the
majority of eyes eventually achieving 5 or more letters at 12 and
24 months. It may hence be hypothesized that patients with less
aggressive lesions benefit from ranibizumab treatment due to
quick edema resolution resulting in a rapid initial improvement
that is sustained in the majority of cases while patients with CFH
CT genotype profit in the long term especially from a combination
of repetitive treatment and the ‘‘advantageous’’ genotype by as of
yet unclear interactions of gene expression changes and lesion
development.
Taken together, we could not find a clear benefit of the loading
phase scheme regarding the long-term VA outcome. The initial
response however is an important predictor for a good long-term
VA course. The converse argument is not true, since initial poor
responders may still experience a favorable long-term VA course.
Furthermore, we were able to confirm the most consistently found
AMD susceptibility variant, the CFH polymorphism, to account
for different responses in treatment even after 24 months. Patients
carrying the CT genotype at CFH rs1061170 have an approxi-
mately three times higher probability to experience a clinically
significant long-term gain in visual acuity with a PRN ranibizu-
mab scheme.
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